跳转至内容
Merck
CN

SML2779

Sigma-Aldrich

Tanaproget

≥98% (HPLC)

别名:

5-(1,4-Dihydro-4,4-dimethyl-2-thioxo-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile, NSP 989

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C16H15N3OS
化学文摘社编号:
分子量:
297.37
MDL编号:
UNSPSC代码:
51111800
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

S=C1Nc2c(cc(cc2)c3[n](c(cc3)C#N)C)C(O1)(C)C

InChI

1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21)

InChI key

PYVFWTPEBMRKSR-UHFFFAOYSA-N

生化/生理作用

Non-steroidal progesterone receptor agonist
Tanaproget is a high affinity, high efficacy and selective orally available non-steroidal progesterone receptor agonist.

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Louis Allott et al.
EJNMMI radiopharmacy and chemistry, 4(1), 1-1 (2019-10-30)
The histological evaluation of estrogen receptor (ER) and progesterone receptor (PR) expression in breast cancer lesions from biopsy tissue can stratify patients to receive endocrine therapy. Furthermore, PR expression can predict response to selective estrogen receptor modulators (SERMs). Current immunohistochemical
Richard C Winneker et al.
Steroids, 73(7), 689-701 (2008-05-13)
Progesterone receptor (PR) modulators have evolved both structurally and mechanistically over the past half-century. Classical steroidal PR agonists continue to play an important role in women's health such as in oral contraception and post-menopausal hormone therapy whereas steroid-based PR antagonists
Jody L Bapst et al.
Contraception, 74(5), 414-418 (2006-10-19)
This study aimed to evaluate the pharmacokinetics, pharmacodynamics and safety of the nonsteroidal progesterone receptor agonist, tanaproget. A randomized, double-blind, placebo-controlled, sequential-group study of ascending single doses of tanaproget was conducted in healthy, 25- to 45-year-old women on cycle days

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持